Menu

Top Stories

Published on Friday, July 24, 2015

2015 Alpha-1 National Conference opens with inspirational Appalachian Trail story, meetings with experts and session on community engagement

2015 Alpha-1 National Conference opens with inspirational Appalachian Trail story, meetings with experts and session on community engagement

The 24th annual National Education Conference of the Alpha-1 community officially began Friday afternoon with a two-hour "Meet the Experts" session at which Alphas were offered the chance to ask questions about both the lung and liver diseases of Alpha-1 to physicians who specialize in both those fields.

Jonathan Maidment tells about his 6-month walk on the Appalachian Trail.

All the doctors involved headed one of the Foundation's Clinical Resources Centers (CRC). There are more than 80 CRCs across the United States, each with doctors experienced in treating Alpha-1, many of them also researchers. The annual CRC Forum, held to update CRC physicians on current developments in research and clinical practice, was held Friday morning in conjunction with the Conference.

Even before it officially opened, the Conference had its first inspirational hit, when Connecticut  Alpha Jonathan Maidment spoke at the lunch sponsored by Grifols about walking the complete Appalachian Trail, some 2,200 miles over two months, in 20414 when Jonathan was 19.

Jonathan, who raised more than $56,000 for the Foundation's research programs, talked about deciding to walk the Trail in honor of his grandmother, who died of Alpha-1 lung disease. He described being forced to take two weeks off from the walk after injuring his feet on the rocky trail; of arriving home after completing the walk, catching up on weeks of old emails, and finding one from his grandfather, who died during Jonathan's walk; and his most frightening experience with animals, not from wildlife, but from a herd of cows he met during the walk, when the whole herd began to chase him down the trail till her made it over a fence.

Jonathan said he is now studying at a local junior college, and when he graduates he plans to walk the Pacific Crest Trail, which is several hundred miles longer than the Appalachian Trail, and runs over mountainous terrain as high as 13,000 feet above sea level.

The stars of Friday morning's breakfast, sponsored by Baxalta, were cartoon characters Mickey, Goofy and Pluto, who entertained both children and adults and posed for photos with many of them.

A session on Community Engagement was an afternoon highlight. Community leaders including AlphaNet Coordinators, all of whom have lung disease related to Alpha-1, support group leaders, fundraising volunteers and Alpha-1 Foundation staff led a session on the key roles that volunteers play in the community, and the many ways that Alphas and their families can get involved, from simply joining a support group to fundraising to advocating for legislation that can help to improve the health and quality of life for Alphas.

Kamyar Afshar, DO, of the University of Southern California, and Jeffrey Teckman, MD, of the University of St. Louis, gave talks on "Alpha-1 Antitrypsin Deficiency 101" on the lung and liver diseases of Alpha-1.

Jean-Marc Quach, executive director of The Alpha-1 Project (TAP), the Foundation's venture philanthropy subsidiary, gave an update on progress in research in which TAP has formed partnerships, including clinical trials begun by Arrowhead Research which has begun a clinical trial of a potential liver therapy in Australia,  and Alnylam Research, which has applied for approval for a trial in the U.K. of its own potential liver therapy.

Robert Sandhaus, MD, PhD, clinical director of the Foundation and medical director of AlphaNet, gave a talk on "Patient Centered Research, What We Do and Where You Fit In," encouraging Alphas to express their needs and opinions to federal authorities in charged of the FDA's new "Patient Centered Research" program.

After hospitality suite receptions by Baxalta, CSL Behring and Grifols, the presenting sponsors of the Conference, a dessert hour followed, with presentations of the Foundation's Building Friends for a Cure awards.

On Thursday, CSL Behring presented its 8th annual "Walk for Breath" celebration at Astor Classics, a museum for classic cars. At dinner, Kevin Kovaleski of CSL encouraged everyone attending to consider signing up for the company's new "My Steps for Healthy Living" program, and praised CSL's partnership with AlphaNet to provide health management services to Alphas with lung disease.

Kovaleski said the "My Steps" program suggests regular walking with a goal of adding 10 percent more steps each month. He introduced Dee Meisner, a Florida Alpha "with an incredible goal."

Meisner, a police officer for 23 years, began climbing mountains in the United States, "starting with little ones, about 3,000" feet, she said. She told about her attempt last year to reach Camp Muir on Mount Rainier in Washington State. She climbed to 9,500 feet before exhaustion and oxygen desaturation forced her to stop.

And she promised, "This August, I plan to make it all the way to Camp Muir, an altitude of more than 10,00 feet!"

The Presenting Conference Sponsors are AlphaNet, Baxalta, CSL Behring and Grifols. Dohmen Life Science Services is the Lead Conference Sponsor.

Building Friends for a Cure awards


Print

Recruitment begins for gene therapy clinical trial for Alpha-1 Antitrypsin Deficiency

Tuesday, December 5, 2017
Enrollment for a trial for a new treatment for Alpha–1 related lung disease begins today. Adverum Biotechnologies, in partnership with the Alpha–1 Foundation will be recruiting patients, as well as healthy ZZ and Znull...
Divider

Your helping hand has an impact for Alphas worldwide

Friday, December 1, 2017
When you donate to the Alpha–1 Foundation, you are helping Alphas everywhere by providing support services to newly diagnosed adults and children, giving access to education to both Alphas and medical professionals, allowing for family...
Divider

UK company acquires license for a potential pill-based Alpha–1 lung therapy

Wednesday, November 1, 2017
Mereo BioPharma Group, a clinical stage, UK-based, biopharmaceutical company focused on rare and specialty diseases, announced that it has reached an agreement with AstraZeneca for an exclusive license, including an option to acquire, AZD9668, an...
Divider

Uncertainty added to health insurance markets

Friday, October 13, 2017
It has been an eventful 24 hours in Washington as President Trump made a number of announcements related to health insurance policy.  First, he signed an executive order that seeks to increase competition by facilitating access to association...
Divider

Celebrating plasma donors worldwide

Wednesday, October 11, 2017
International Plasma Awareness Week (IPAW) brings awareness to the importance of plasma donors worldwide. “During PPTA’s International Plasma Awareness Week, we want to thank all the donors that make life sustaining Alpha–1...
Divider

Medicare says 2018 to offer more health coverage choices and decreased premiums

Friday, September 29, 2017
Today, the Centers for Medicare & Medicaid Services (CMS) announced that people with Medicare will have more choices and options for their Medicare coverage in 2018. As CMS releases the benefit and premium information for Medicare health and...
Divider

Record-breaking year for Team Alpha-1 at Escape to the Cape

Friday, September 29, 2017
As summer wanes and fall begins, Team Alpha–1 is decompressing from another successful Autumn Escape Bike Trek. This year has seen many firsts over our 23-year history of participating in this event with the American Lung Association of the...
Divider

Bob Campbell passes away, Foundation Communications Director, former AlphaNet Coordinator

Friday, July 28, 2017
Our dear friend and colleague, Bob Campbell passed Thursday evening with his wife Elizabeth by his side. Campbell began his Alpha-1 journey when he was diagnosed by his allergist. In 2002, he took the leap and became an AlphaNet...
Divider

Kamada Submits Proposed Phase 3 Protocol to FDA for Inhaled Alpha-1 Antitrypsin Treatment

Friday, July 21, 2017
Kamada Ltd., a plasma-derived protein therapeutics company focused on orphan indications, today announced that the Company has submitted to the U.S. Food and Drug Administration (FDA) for review a proposed pivotal Phase 3 protocol for its...
Divider

Foundation president and CEO urges Alphas to find their place in the Alpha-1 Community

Thursday, June 29, 2017
CHICAGO, Illinois – Henry Moehring, president and CEO of the Alpha–1 Foundation, presided over the 26th and largest National Education Conference of the Alpha–1 community since its inception, he said in his Foundation update...
Divider

Alpha-1 Foundation Accepting Proposals for the John W. Walsh Translational Research Award in Alpha-1 Antitrypsin Deficiency

Wednesday, June 28, 2017
The Alpha-1 Foundation is committed to finding a cure for Alpha-1 Antitrypsin Deficiency and to improving the lives of people affected by Alpha-1 worldwide. This award is named after John W. Walsh, who dedicated his life’s work to finding...
Divider

Barbara Pusey honored in memoriam at Alpha–1 awards and recognition night

Monday, June 26, 2017
Barbara Pusey, who was the first AlphaNet Coordinator for the augmentation therapy marketed in the United States as Zemaira and was a major influence in building the AlphaNet Zemaira program into what it is today, was recognized posthumously, with...
Divider
12345678910Last

Article Search

Enter keywords in text box and click Search button for results.